Human scientists reach a target-binding antibody by four broad routes, and they are usually combined rather than used in isolation.
Immunization and hybridoma discovery uses biology as the search engine. An animal is immunized with the target antigen; its immune system generates and selects B cells whose antibodies bind that antigen. The scientist then fuses a B cell with a myeloma cell to create a hybridoma — an immortal cell line that keeps secreting the same antibody. The output is a monoclonal antibody with a known, reproducible sequence.
Display-based selection builds the diversity artificially. A large library of antibody variants is displayed on the surface of phage particles, each particle carrying the gene for the variant it displays. The library is exposed to immobilized target; non-binders are washed away; bound variants are recovered and re-amplified. Because the variant and its gene travel together, a recovered binder can be identified and produced.
Rational, structure-guided engineering starts from knowledge rather than from a library. If the structure of the antibody–antigen interface is known or can be modeled, the scientist can identify which residues contact the antigen and change them deliberately.
Affinity maturation is not a separate starting point but a loop applied to candidates from any of the other routes: mutate the binding region, express the variants, measure binding, and keep the best.
All four routes converge on the same deliverable — a defined antibody sequence that binds the chosen target — and all four are steered by human decisions about target, format, and acceptance criteria.